U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer

In 2019, the FDA granted accelerated approval for PADCEV for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and a platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery, or in a locally advanced or metastatic urothelial cancer setting. The Read more…

Cost Analysis of Biosimilar vs Reference Rituximab for Treating CLL and Other Diseases

Rituximab-abbs may have more economic benefits compared to rituximab in patients with non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis, according to a study presented at the virtual 2021 ASCO Annual Meeting. These findings were presented by Elizabeth James, MD, Aventine Consulting, LLC, Read more…

Clinical and Economic Burden of First-Line Chemoimmunotherapy for CLL/SLL

Between high-risk and nonhigh-risk patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) initiating first-line chemoimmunotherapy, high-risk patients experience greater risk of next treatment or death, treatment failure, and higher costs, according to a real-world study presented at the 2021 ASCO Annual Meeting. The economic burden for patients Read more…